{"protocolSection": {"identificationModule": {"nctId": "NCT01556997", "orgStudyIdInfo": {"id": "X985400"}, "organization": {"fullName": "Symplmed Pharmaceuticals LLC", "class": "INDUSTRY"}, "briefTitle": "Perindopril Amlodipine for the Treatment of Hypertension", "officialTitle": "Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension", "acronym": "PATH"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02"}, "primaryCompletionDateStruct": {"date": "2013-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-15", "studyFirstSubmitQcDate": "2012-03-15", "studyFirstPostDateStruct": {"date": "2012-03-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-28", "resultsFirstSubmitQcDate": "2015-07-28", "resultsFirstPostDateStruct": {"date": "2015-08-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-08", "lastUpdatePostDateStruct": {"date": "2015-09-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Symplmed Pharmaceuticals LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Hypertension", "Essential Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 837, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "XOMA 985", "type": "EXPERIMENTAL", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)", "interventionNames": ["Drug: XOMA 985"]}, {"label": "Amlodipine Besylate (AMLb)", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Amlodipine Besylate"]}, {"label": "Perindopril Erbumine (PERe)", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Perindopril Erbumine"]}], "interventions": [{"type": "DRUG", "name": "XOMA 985", "description": "PERa/AMLb capsule taken once daily by mouth for six weeks", "armGroupLabels": ["XOMA 985"]}, {"type": "DRUG", "name": "Amlodipine Besylate", "description": "AMLb capsule taken once daily by mouth for six weeks", "armGroupLabels": ["Amlodipine Besylate (AMLb)"]}, {"type": "DRUG", "name": "Perindopril Erbumine", "description": "PERe capsule taken once daily by mouth for six weeks", "armGroupLabels": ["Perindopril Erbumine (PERe)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).", "timeFrame": "Day 0 to Day 42"}], "secondaryOutcomes": [{"measure": "Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).", "timeFrame": "Day 0 to Day 42"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Essential hypertension\n* For female subjects, a negative serum pregnancy test\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Night shift workers whose work hours include midnight to 4:00 a.m.\n* Secondary hypertension\n* An arm size that precludes the use of the digital blood pressure monitor cuff (arm size \\> 42 cm)\n* Renal dysfunction, severe renal impairment, bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, subjects with only 1 kidney, or post-renal transplant subjects\n* Female subjects who are pregnant, planning to become pregnant\n* History of malignancy within 5 years\n* Primary aldosteronism\n* Heart failure (NYHA functional class 3-4), hypertrophic obstructive cardiomyopathy, or hemodynamically relevant stenosis of the aortic or mitral valve\n* Significant cardiac arrhythmias, MI, stroke, CABG, PTCA, unstable angina\n* Known hypersensitivity to any component of the study drugs\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"city": "Huntsville", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"city": "Muscle Shoals", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"city": "Glendale", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"city": "Greenbrae", "state": "California", "country": "United States", "geoPoint": {"lat": 37.94854, "lon": -122.5247}}, {"city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"city": "Deland", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"city": "Ft. Lauderdale", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"city": "Palm Harbor", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.07807, "lon": -82.76371}}, {"city": "Port Orange", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.13832, "lon": -80.99561}}, {"city": "Marietta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"city": "Gurnee", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 42.3703, "lon": -87.90202}}, {"city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"city": "Wichita", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"city": "Louisville", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"city": "Metairie", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"city": "Auburn", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"city": "Olive Branch", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 34.96176, "lon": -89.82953}}, {"city": "Butte", "state": "Montana", "country": "United States", "geoPoint": {"lat": 46.00382, "lon": -112.53474}}, {"city": "Berlin", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.79123, "lon": -74.92905}}, {"city": "Greensboro", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"city": "Hickory", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Columbus", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"city": "Kettering", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"city": "Lyndhurst", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.52005, "lon": -81.48873}}, {"city": "Marion", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"city": "Eugene", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"city": "Mount Pleasant", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"city": "Simpsonville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"city": "Bristol", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"city": "Austin", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"city": "Corpus Christi", "state": "Texas", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Ft. Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "Katy", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Salt Lake City", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"city": "Norfolk", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"city": "Richmond", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "XOMA 985", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)\n\nXOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks"}, {"id": "FG001", "title": "Amlodipine Besylate (AMLb)", "description": "Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks"}, {"id": "FG002", "title": "Perindopril Erbumine (PERe)", "description": "Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "279"}, {"groupId": "FG001", "numSubjects": "280"}, {"groupId": "FG002", "numSubjects": "278"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "253"}, {"groupId": "FG001", "numSubjects": "252"}, {"groupId": "FG002", "numSubjects": "246"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "28"}, {"groupId": "FG002", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "XOMA 985", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)\n\nXOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks"}, {"id": "BG001", "title": "Amlodipine Besylate (AMLb)", "description": "Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks"}, {"id": "BG002", "title": "Perindopril Erbumine (PERe)", "description": "Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "279"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "278"}, {"groupId": "BG003", "value": "837"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "261"}, {"groupId": "BG001", "value": "262"}, {"groupId": "BG002", "value": "254"}, {"groupId": "BG003", "value": "777"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "143"}, {"groupId": "BG003", "value": "407"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "145"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "430"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "52"}, {"groupId": "BG003", "value": "142"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "232"}, {"groupId": "BG001", "value": "237"}, {"groupId": "BG002", "value": "226"}, {"groupId": "BG003", "value": "695"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "96"}, {"groupId": "BG003", "value": "287"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "179"}, {"groupId": "BG001", "value": "181"}, {"groupId": "BG002", "value": "180"}, {"groupId": "BG003", "value": "540"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "96"}, {"groupId": "BG003", "value": "287"}]}]}, {"title": "Non-black", "categories": [{"measurements": [{"groupId": "BG000", "value": "184"}, {"groupId": "BG001", "value": "184"}, {"groupId": "BG002", "value": "182"}, {"groupId": "BG003", "value": "550"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "279"}, {"groupId": "BG001", "value": "280"}, {"groupId": "BG002", "value": "278"}, {"groupId": "BG003", "value": "837"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).", "populationDescription": "The Analysis Population for the Primary Outcome (Change from baseline to end of treatment in the mean seated trough cuff diastolic blood pressure (DBP)) consists of the Intent-to-treat population for the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 0 to Day 42", "groups": [{"id": "OG000", "title": "XOMA 985", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)\n\nXOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks"}, {"id": "OG001", "title": "Amlodipine Besylate (AMLb)", "description": "Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks"}, {"id": "OG002", "title": "Perindopril Erbumine (PERe)", "description": "Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "275"}, {"groupId": "OG002", "value": "274"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.7", "spread": "8.38"}, {"groupId": "OG001", "value": "-13.2", "spread": "8.33"}, {"groupId": "OG002", "value": "-9.5", "spread": "8.77"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.025", "pValueComment": "The statistical model was an analysis of covariance model with treatment as the main effect and baseline DBP (\\<100 mmHg versus \u2265100 mmHg), current type 2 diabetes status (yes versus no), and race (black versus non-black) as covariates.", "statisticalMethod": "ANCOVA", "ciNumSides": "ONE_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).", "populationDescription": "The Analysis Population for the Secondary Outcome (Change from baseline to end of treatment in the mean seated trough cuff systolic blood pressure (SBP)) consists of the Intent-to-treat population for the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 0 to Day 42", "groups": [{"id": "OG000", "title": "XOMA 985", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)\n\nXOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks"}, {"id": "OG001", "title": "Amlodipine Besylate (AMLb)", "description": "Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks"}, {"id": "OG002", "title": "Perindopril Erbumine (PERe)", "description": "Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "275"}, {"groupId": "OG002", "value": "274"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.4", "spread": "13.86"}, {"groupId": "OG001", "value": "-19.6", "spread": "15.62"}, {"groupId": "OG002", "value": "-13.4", "spread": "14.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.025", "pValueComment": "The statistical model was an analysis of covariance model with treatment as the main effect and baseline DBP (\\<100 mmHg versus \u2265100 mmHg), current type 2 diabetes status (yes versus no), and race (black versus non-black) as covariates.", "statisticalMethod": "ANCOVA", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "description": "AE reporting began with Visit 1 and continued through 14 days after last dose, unless an unresolved AE was still being followed. At each evaluation, the Investigator determined whether any AEs occurred based on the criteria and definition of an AE or SAE. AEs may have been directly observed, elicited by Investigator, or volunteered by subjects.", "eventGroups": [{"id": "EG000", "title": "XOMA 985", "description": "fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)\n\nXOMA 985: PERa/AMLb capsule taken once daily by mouth for six weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 279, "otherNumAffected": 75, "otherNumAtRisk": 279}, {"id": "EG001", "title": "Amlodipine Besylate (AMLb)", "description": "Amlodipine Besylate: AMLb capsule taken once daily by mouth for six weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 280, "otherNumAffected": 68, "otherNumAtRisk": 280}, {"id": "EG002", "title": "Perindopril Erbumine (PERe)", "description": "Perindopril Erbumine: PERe capsule taken once daily by mouth for six weeks", "seriousNumAffected": 2, "seriousNumAtRisk": 278, "otherNumAffected": 53, "otherNumAtRisk": 278}], "seriousEvents": [{"term": "Lip Swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 278}]}, {"term": "Renal Failure Acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 278}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 278}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 278}]}, {"term": "Gastrointestinal Hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 278}]}, {"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 278}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 278}]}], "otherEvents": [{"term": "Edema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 278}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 278}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 278}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 278}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 278}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 278}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 278}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 278}]}, {"term": "Alanine amniotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 278}]}, {"term": "Aspartate amniotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 278}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 278}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 278}]}, {"term": "Hematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 278}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 279}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 280}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 278}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Jeff Feldstein, Sr. Vice President and CMO", "organization": "Symplmed Pharmaceuticals LLC", "email": "feldstein@symplmed.com", "phone": "888-552-9769"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000020913", "term": "Perindopril"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Valproic Acid", "relevance": "HIGH"}, {"id": "M22648", "name": "Perindopril", "asFound": "Respond to", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "T1", "name": "Arginine", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}